Skip to main content
SpringerLink
Log in

OnabotulinumtoxinA (Botox®): A Review of its Use in the Treatment of Urinary Incontinence in Patients with Multiple Sclerosis or Subcervical Spinal Cord Injury

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

OnabotulinumtoxinA (BOTOX®) is a type A neurotoxin derived from Clostridium botulinum bacteria that is approved as treatment for urinary incontinence (UI) in patients with neurogenic detrusor overactivity resulting from multiple sclerosis (MS) or subcervical spinal cord injury (SCI) who are not adequately treated by antimuscarinics. This article reviews the pharmacology of intradetrusor onabotulinumtoxinA in this indication. The presumed mode of action of onabotulinumtoxinA in bladder disorders is by interfering with efferent innervation of the detrusor muscle and afferent pathways involved in the micturition reflex. In phase III trials in adult patients with MS or SCI with UI who were not adequately treated with antimuscarinics, intradetrusor onabotulinumtoxinA 200 U produced significantly greater mean changes (reductions) from baseline in UI episodes/week at week 6 than placebo (primary endpoint). Similar significant benefits of intradetrusor onabotulinumtoxinA 200 U over placebo were observed on other UI, urodynamic, health-related quality of life and treatment satisfaction endpoints. Intradetrusor onabotulinumtoxinA 200 U was generally well tolerated, with the most frequent adverse events being urinary tract infections and urinary retention. Few patients discontinued treatment because of adverse events. Based on interim analyses of an extension study of the phase III trials, repeat injections of onabotulinumtoxinA 200 U were similarly efficacious and well tolerated. Intradetrusor onabotulinumtoxinA represents a clinically important advance in the therapy of UI in patients with MS or SCI who have not responded to antimuscarinics or who are unable to tolerate antimuscarinics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Benarroch EE. Neural control of the bladder: recent advances and neurologic implications. Neurology. 2010;75(20):1839–46.

    Article  PubMed  Google Scholar 

  2. Nicholas R, Young C, Friede T. Bladder symptoms in multiple sclerosis: a review of pathophysiology and management. Expert Opin Drug Saf. 2010;9(6):905–15.

    Article  PubMed  Google Scholar 

  3. Tubaro A, Puccini F, De Nunzio C, et al. The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review. Curr Urol Rep. 2012;13:335–42.

    Article  PubMed  CAS  Google Scholar 

  4. Sahai A, Cortes E, Seth J, et al. Neurogenic detrusor overactivity in patients with spinal cord injury: evaluation and management. Curr Urol Rep. 2011;12(6):404–12.

    Article  PubMed  Google Scholar 

  5. Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Med. 2009;85:552–9.

    Article  CAS  Google Scholar 

  6. Andersson K-E, Chapple CR, Cardozo L, et al. Pharmacological treatment of urinary incontinence: In Abrams P, Cardoza L, Khoury S, Wein A (eds) Incontinence. Health Publication Ltd; 2009. Available from: http://www.ics.org/publications/ici_4/files-book/comite-8.pdf.

  7. del Popolo G, Mencarini M, Nelli F, et al. Controversy over the pharmacological treatments of storage symptoms in spinal cord injury patients. Spinal Cord. 2012;50(1):8–13.

    Article  PubMed  Google Scholar 

  8. Schulte-Mattler WJ. Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety. CNS Drugs. 2008;22(9):725–38.

    Article  PubMed  CAS  Google Scholar 

  9. Electronic Medicines Agency (emc). BOTOX 100 Allergan units powder for solution for injection: summary of product characteristics. 2014. http://www.medicines.org.uk/emc/medicine/112/SPC/BOTOX+100+Units/. Accessed 15 July 2014.

  10. Charrua A, Avelino A, Cruz F. Modulation of urinary bladder innervation: TRPV1 and botulinum toxin A. In: Andersson K-E, Michel MC, editors. Urinary tract. New York: Springer New York; 2011. p. 345–74.

    Chapter  Google Scholar 

  11. Aoki KR. Pharmacology and immunology of botulinum neurotoxins. Int Ophthalmol Clin. 2005;45(3):25–37.

    Article  PubMed  Google Scholar 

  12. Andersson K-E. New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA. Ther Clin Risk Manag. 2013;9:161–70.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Takahashi R, Yunoki T, Naito S, et al. Differential effects of botulinum neurotoxin A on bladder contractile responses to activation of efferent nerves, smooth muscles and afferent nerves in rats. J Urol. 2012;188(5):1993–9.

    Article  PubMed  CAS  Google Scholar 

  14. Collins VM, Daly DM, Liaskos M, et al. OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium. BJU Int. 2013;112(7):1018–26.

    PubMed  CAS  Google Scholar 

  15. Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibres following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005;174(3):977–83.

    Article  PubMed  CAS  Google Scholar 

  16. Conte A, Giannantoni A, Proietti S, et al. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity. Eur J Neurol. 2012;19(5):725–32.

    Article  PubMed  CAS  Google Scholar 

  17. Giannantoni A, Di Stasi SM, Nardicchi V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol. 2006;175(6):2341–4.

    Article  PubMed  CAS  Google Scholar 

  18. Liu H-T, Chancellor MB, Kuo H-C. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol. 2009;56(4):700–6.

    Article  PubMed  CAS  Google Scholar 

  19. Giannantoni A, Conte A, Farfariello V, et al. Onabotulinumtoxin-A intradetrusorial injections modulate bladder expression of NGF, TrkA, p75 and TRPV1 in patients with detrusor overactivity. Pharmacol Res. 2013;68(1):118–24.

    Article  PubMed  CAS  Google Scholar 

  20. Elkelini MS, Bagli DJ, Fehlings M, et al. Effects of intravesical onabotulinumtoxinA on bladder dysfunction and autonomic dysreflexia after spinal cord injury: role of nerve growth factor. BJU Int. 2012;109(3):402–7.

    Article  PubMed  CAS  Google Scholar 

  21. Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX) across multiple indications. Mov Disord. 2010;25(13):2211–8.

    Article  PubMed  Google Scholar 

  22. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–50.

    Article  PubMed  CAS  Google Scholar 

  23. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131–9.

    Article  PubMed  CAS  Google Scholar 

  24. Kennelly M, Dmochowski R, Ethans K, et al. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. Urology. 2013;81(3):491–7.

    Article  PubMed  Google Scholar 

  25. Schurch B, de Séze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196–200.

    Article  PubMed  CAS  Google Scholar 

  26. Herschorn S, Gajewski J, Ethans K, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185(6):2229–35.

    Article  PubMed  CAS  Google Scholar 

  27. Schurch B, Denys P, Kozma CM, et al. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol. 2007;52(3):850–8.

    Article  PubMed  CAS  Google Scholar 

  28. Ginsberg D, Cruz F, Herschorn S, et al. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of concomitant anticholinergic use or neurologic etiology. Adv Ther. 2013;30(9):819–33.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  29. Sussman D, Patel V, Del Popolo G, et al. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32(3):242–9.

    Article  PubMed  CAS  Google Scholar 

  30. Chancellor MB, Patel V, Leng WW, et al. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. Neurology. 2013;81(9):841–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  31. Giannantoni A, Mearini E, Del Zingaro M, et al. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol. 2009;55(3):705–11.

    Article  PubMed  CAS  Google Scholar 

  32. Malmberg L, Karadzic V. Effects of repeated botulinum toxin A injection therapy in patients with sympthomatic neurogenic detrusor overactivity—a 3-year follow up [abstract no. 168]. Neurourol Urodyn. 2009;28(7):610–1.

    Google Scholar 

  33. Kuo H-C, Liu S-H. Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries. Neurourol Urodyn. 2011;30(8):1541–5.

    Article  PubMed  Google Scholar 

  34. Khan S, Game X, Kalsi V, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011;185(4):1344–9.

    Article  PubMed  CAS  Google Scholar 

  35. Chen SF, Kuo HC. Lack of consistent therapeutic effects of repeated 200 U onabotulinumtoxina detrusor injections on urinary incontinence in chronic spinal cord injured patients (abstract no. 1656). J Urol. 2012. doi:10.1016/j.juro.2012.02.1488.

    Google Scholar 

  36. Panicker J, Schulte-Baukloh H, Del Popolo G, et al. Consistent long-term efficacy of onabotulinumtoxinA in patients with neurogenic detrusor overactivity due to multiple sclerosis: an interim analysis after five treatment cycles [abstract no. 168]. European Committee for Treatment and Research in Multiple Sclerosis; 2–5 October 2013; Copenhagen.

  37. Kennelly M, Jenkins B, Zhou J, et al. Consistent and persistent long-term efficacy after repeat onabotulinumtoxinA detrusor injections in patients with neurogenic detrusor overactivity [abstract no. 1717]. J Urol. 2013;1:e706–7.

    Article  Google Scholar 

  38. Rovner E, Dmochowski R, Chapple C, et al. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32(8):1109–15.

    Article  PubMed  CAS  Google Scholar 

  39. De Laet K, Wyndaele J-J. Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord. 2005;43(7):397–9.

    Article  PubMed  Google Scholar 

  40. Pannek J, Stöhrer M, Blok B, et al. Guidelines on neurogenic lower urinary tract dysfunction. European Association of Urology. 2011. http://www.uroweb.org/gls/pdf/17_Neurogenic%20LUTS.pdf. Accessed 15 July 2014.

  41. Samson G, Cardenas DD. Neurogenic bladder in spinal cord injury. Phys Med Rehabil Clin N Am. 2007;18:255–74.

    Article  PubMed  Google Scholar 

  42. National Institute for Health and Clinical Excellence. Urinary incontinence in neurological disease: management of lower urinary tract dysfunction in neurological disease. 2012. http://guidance.nice.org.uk/CG148/Guidance/pdf/English. Accessed 15 July 2014.

  43. Gomelsky A, Dmochowski RR. Update on the management of overactive bladder: patient considerations and adherence. J Urol. 2011;3(1):7–17.

    Google Scholar 

  44. Nicholas RS, Friede T, Hollis S, et al. Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev. 2009;1:CD004193.

    PubMed  Google Scholar 

  45. Dowson C, Khan MS, Dasgupta P, et al. Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity. Nat Rev Urol. 2010;7(12):661–7.

    Article  PubMed  CAS  Google Scholar 

  46. Wefer B, Ehlken B, Bremer J, et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. World J Urol. 2010;28(3):385–90.

    Article  PubMed  Google Scholar 

  47. Gamé X, Castel-Lacanal E, Bentaleb Y, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol. 2008;53(3):613–8.

    Article  PubMed  Google Scholar 

  48. Schurch B, Denys P, Kozma CM, et al. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil. 2007;88(5):646–52.

    Article  PubMed  Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding. Mark Sanford is a salaried employee of Adis/Springer. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand

    Mark Sanford

Authors
  1. Mark Sanford
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Sanford.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sanford, M. OnabotulinumtoxinA (Botox®): A Review of its Use in the Treatment of Urinary Incontinence in Patients with Multiple Sclerosis or Subcervical Spinal Cord Injury. Drugs 74, 1659–1672 (2014). https://doi.org/10.1007/s40265-014-0271-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-014-0271-z

Keywords

Search

Navigation